Picture of Viemed Healthcare logo

VMD — Viemed Healthcare News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareBalancedSmall CapNeutral

Viemed Healthcare Q2 revenue rises on ventilator patient growth

Viemed Healthcare Q2 revenue rises on ventilator patient growth


Overview

  • US home healthcare provider's Q2 revenue rose 24% yr/yr to a record high

  • Adjusted EBITDA for Q2 fell 4% yr/yr due to prior-year non-recurring gain

  • Company repurchased and cancelled 530,802 for $5.1 mln during Q2


Outlook

  • Viemed raises 2026 net revenue guidance to $314 mln-$320 mln from $312 mln-$320 mln

  • Company revises 2026 Adjusted EBITDA outlook to $64 mln-$68 mln from $65 mln-$69 mln

  • Net capital expenditures for 2026 now seen at 8.5%-10.0% of net revenue, down from 9.0%-10.5%


Result Drivers

  • VENTILATOR PATIENT GROWTH - Co said record ventilator patient census and strong setup activity contributed to revenue growth

  • PAP AND RESUPPLY EXPANSION - Co cited record PAP therapy volume and continued expansion in resupply and maternal health as supporting growth

  • DIVERSIFIED PLATFORM - CEO said results reflect a more diversified business with multiple growth engines and ongoing investments in technology and patient care


Company press release: ID:nACS7qYBpa


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Revenue

Meet

$78.10 mln

$78.10 mln (2 Analysts)

Q2 EPS

$0.07

Q2 Net Income

$2.90 mln

Q2 Gross Profit

$45.05 mln

Q2 Income from Operations

$4.46 mln

Q2 Pretax Profit

$4.05 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the healthcare facilities & services peer group is "buy"

  • Wall Street's median 12-month price target for Viemed Healthcare Inc is $13.00, about 11.4% above its July 31 closing price of $11.67

  • The stock recently traded at 22 times the next 12-month earnings vs. a P/E of 19 three months ago


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Viemed Healthcare

See all news